Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Repare Therapeutics Inc. RPTX
$10.19
+$0.1 (0.99%)
На 18:02, 12 мая 2023
+128.95%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
446867298.00000000
-
week52high
18.68
-
week52low
8.07
-
Revenue
131830000
-
P/E TTM
-15
-
Beta
0.07646000
-
EPS
-0.70000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 20:05
Описание компании
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Overweight | Overweight | 08 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 06 июн 2022 г. |
| Piper Sandler | Overweight | Overweight | 02 июн 2022 г. |
| Stifel | Hold | Buy | 12 апр 2022 г. |
| Stifel | Buy | 23 сент 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 17 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Forte Steve | A | 111050 | 111050 | 30 янв 2023 г. |
| Forte Steve | A | 30687 | 24530 | 30 янв 2023 г. |
| Segal Lloyd Mitchell | A | 344200 | 344200 | 30 янв 2023 г. |
| Segal Lloyd Mitchell | A | 84677 | 78550 | 30 янв 2023 г. |
| Koehler Maria | A | 119250 | 119250 | 30 янв 2023 г. |
| Koehler Maria | A | 175963 | 26450 | 30 янв 2023 г. |
| Zinda Michael | A | 97100 | 97100 | 30 янв 2023 г. |
| Zinda Michael | A | 70591 | 24550 | 30 янв 2023 г. |
| Jerel Davis | A | 25131 | 3014 | 29 дек 2022 г. |
| Jerel Davis | D | 0 | 4721 | 29 дек 2022 г. |
Новостная лента
Repare Therapeutics Inc. (RPTX) Just Overtook the 20-Day Moving Average
Zacks Investment Research
02 дек 2022 г. в 11:17
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Repare Therapeutics Inc. (RPTX) Q3 Earnings and Revenues Surpass Estimates
Zacks Investment Research
09 ноя 2022 г. в 18:48
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 955% and 160.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners
Seeking Alpha
07 сент 2022 г. в 09:10
Repare Therapeutics' shares have lost roughly half their value over the past year. Roche's deal for ATR inhibitor camonsertib validated the company's SNIPRx and STEP2 platform technologies, a unique take on the emerging field of synthetic lethality.
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates
Zacks Investment Research
04 авг 2022 г. в 20:18
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -5.81% and 68.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech ETF Tops in June: 5 Stocks That Outperform
Zacks Investment Research
30 июн 2022 г. в 14:52
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.